Methods	8 week randomised double blind study
Participants	Diagnosis: DSM-IV major depressive disorder Setting: In- and outpatients
Interventions	1. Mirtazapine: 30-60 mg/day, N = 147 2. Fluoxetine: 20-40 mg/day, N = 152 Flexible dosing scheduling
Outcomes	The measure used for response and remission in the review: 17-item HAM-D Other measures: MADRS, CGI-Severity, Leeds Sleep Evaluation Questionnaire, Quality of Life, Enjoyment and Satisfaction Questionnaire, Changes in Sezual Functioning Questionnaire
Notes
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: “randomised” Comment: No further information provided.
Allocation concealment (selection bias)	Unclear risk	Comment: The method of allocation is not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Quote: “double-blind” Comment: No further information provided.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	The numbers of dropouts in the both arms are not specified.
Selective reporting (reporting bias)	Low risk	The response outcome at the end of acute-phase treatment is provided in the figure as the proportion of the participants who achieved this
Free of Sponsorship bias?	High risk	The funding source is the pharmaceutical company of mirtazapine